MERCK & CO INC

Merck’s stock gains after Morgan Stanley’s upgrade and CHMP’s positive win for WINREVAIR, hinting at a modest upside and expanded PAH treatment prospects.

Merck’s Q3 2025 earnings jump—$5.8 bn profit and $2.58 EPS—boosts outlook as oncology, animal‑health growth and new lung‑cancer vaccines drive upside.

Merck & Co Inc has reported adjusted earnings that exceeded market expectations, demonstrating its resilience and stability in a time of market uncertainty.